These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16517843)

  • 21. Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A.
    Watanabe K; Yoshioka K; Yano M; Ishigami M; Ukai K; Ito H; Miyata F; Mizutani T; Goto H
    J Med Virol; 2005 Apr; 75(4):504-12. PubMed ID: 15714488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
    Afzal S; Idrees M; Akram M; Awan Z; Khubaib B; Aftab M; Fatima Z; Badar S; Hussain A
    Virol J; 2010 Dec; 7():377. PubMed ID: 21194456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
    Polyak SJ; Nousbaum JB; Larson AM; Cotler S; Carithers RL; Gretch DR
    J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions.
    Schinkel J; Spaan WJ; Kroes AC
    Antivir Ther; 2004 Apr; 9(2):275-86. PubMed ID: 15134190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
    Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma.
    Hung CH; Chen CH; Lee CM; Wu CM; Hu TH; Wang JH; Yen YH; Lu SN
    J Viral Hepat; 2008 Jan; 15(1):58-65. PubMed ID: 18088246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations.
    Durante Mangoni E; Forton DM; Ruggiero G; Karayiannis P
    J Med Virol; 2003 May; 70(1):62-73. PubMed ID: 12629645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.
    Sáiz JC; López-Labrador FX; Ampurdanés S; Dopazo J; Forns X; Sánchez-Tapias JM; Rodés J
    J Infect Dis; 1998 Apr; 177(4):839-47. PubMed ID: 9534954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
    Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
    Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
    Squadrito G; Raffa G; Restuccia T; Pollicino T; Brancatelli S; Raimondo G
    J Viral Hepat; 2002 Sep; 9(5):360-9. PubMed ID: 12225331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region.
    Brillet R; Penin F; Hezode C; Chouteau P; Dhumeaux D; Pawlotsky JM
    J Infect Dis; 2007 Feb; 195(3):432-41. PubMed ID: 17205483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy.
    Quer J; Murillo P; Martell M; Gómez J; Esteban JI; Esteban R; Guardia J
    J Viral Hepat; 2004 Jan; 11(1):45-54. PubMed ID: 14738557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.